When sorting patients according to the proportion of CD73+ cancer cells, we found that CD73 abundance was associated with poor prognosis in patients (survival median of 396 days and 729 days for CD73 high and low, respectively; Fig. 7K). This evidence concerns the gene NT5E and cancer.